Patents by Inventor Hirobumi Senga

Hirobumi Senga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210128699
    Abstract: Provided are a neutrophil activation regulator and a therapeutic agent against diseases caused by neutrophil activation. A thrombin-like enzyme is used as an active ingredient of the neutrophil activation regulator and the therapeutic agent against diseases caused by neutrophil activation.
    Type: Application
    Filed: January 12, 2018
    Publication date: May 6, 2021
    Applicants: TOBISHI PHARMACEUTICAL CO., LTD., TOKAI UNIVERSITY EDUCATIONAL SYSTEM
    Inventors: Haruchika MASUDA, Takayuki ASAHARA, Hirobumi SENGA
  • Patent number: 10624910
    Abstract: The present invention provides an agent for reducing a side effect of an anticancer drug, which comprises a thrombin-like enzyme.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: April 21, 2020
    Assignee: TOBISHI PHARMACEUTICAL CO., LTD.
    Inventors: Hirobumi Senga, Yongling Wan
  • Patent number: 8795655
    Abstract: The present invention provides a therapeutic agent for a lower urinary tract disease such as cystitis, interstitial cystitis, prostatitis, benign prostatic hyperplasia etc., which are considered as refractory disease, and an agent for improving a lower urinary tract symptom associated with the lower urinary tract disease.
    Type: Grant
    Filed: July 1, 2009
    Date of Patent: August 5, 2014
    Assignee: Tobishi Pharmaceutical Co., Ltd.
    Inventors: Hirobumi Senga, Yongling Wan, Masato Honma
  • Patent number: 8481047
    Abstract: A malignant tumor-inhibiting preparation is provided which comprises Des A fibrin and therefore can inhibit the spreading and migration of malignant tumor cells and thereby can inhibit the malignant tumors.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: July 9, 2013
    Assignee: Tobishi Pharmaceutical Co., Ltd.
    Inventors: Hirobumi Senga, Caixia Li, Yongling Wan, Lishui Chang
  • Publication number: 20110150858
    Abstract: The present invention provides a therapeutic agent for a lower urinary tract disease such as cystitis, interstitial cystitis, prostatitis, benign prostatic hyperplasia etc., which are considered as refractory disease, and an agent for improving a lower urinary tract symptom associated with the lower urinary tract disease.
    Type: Application
    Filed: July 1, 2009
    Publication date: June 23, 2011
    Applicant: Tobishi Pharmaceutical Co., Ltd.
    Inventors: Hirobumi Senga, Yongling Wan, Masato Honma
  • Publication number: 20100247510
    Abstract: The present invention provides an agent for reducing a side effect of an anticancer drug, which comprises a thrombin-like enzyme.
    Type: Application
    Filed: December 12, 2008
    Publication date: September 30, 2010
    Applicant: TOBISHI PHARMACEUTICAL CO., LTD.
    Inventors: Hirobumi Senga, Yongling Wan
  • Patent number: 7691371
    Abstract: A preparation for inhibiting local invasion of malignant tumors is provided which comprises batroxobin and therefore can inhibit local invasion of malignant tumors. A preparation for encapsulating malignant tumor tissues is also provided which comprises batroxobin and therefore can cause or promote formation of capsule-like tissue around malignant tumor tissues.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: April 6, 2010
    Assignee: Tobishi Pharmaceutical Co., Ltd.
    Inventors: Hirobumi Senga, Yongling Wan, Lishui Chang
  • Publication number: 20100034803
    Abstract: The present invention provides an activating agent of stem cells and/or progenitor cells comprising a thrombin-like enzyme which can be used in regenerative medicine, and particularly in regenerative medicine utilizing self-regeneration, acting promptly and moderately depending on the state of advancement and the degree of injured organs and/or tissues to which regenerative medicine is applied, with few or no side effects. The present invention also provides a method for activating stem cells and/or progenitor cells in an animal comprising the step of administering to the animal an effective amount of a thrombin-like enzyme and use of the thrombin-like enzyme for activating stem cells and/or progenitor cells.
    Type: Application
    Filed: October 2, 2006
    Publication date: February 11, 2010
    Applicant: TOBISHI PHARMACEUTICAL CO., LTD.
    Inventors: Hirobumi Senga, Zhongchao Han, Dingfang Cai, Li Li
  • Publication number: 20090018062
    Abstract: A malignant tumor-inhibiting preparation is provided which comprises Des A fibrin and therefore can inhibit the spreading and migration of malignant tumor cells and thereby can inhibit the malignant tumors.
    Type: Application
    Filed: June 15, 2007
    Publication date: January 15, 2009
    Applicant: Tobishi Pharmaceutical Co., Ltd.
    Inventors: Hirobumi Senga, Caixia Li, Yongling Wan, Lishui Chang
  • Publication number: 20070104706
    Abstract: A preparation for inhibiting local invasion of malignant tumors is provided which comprises batroxobin and therefore can inhibit local invasion of malignant tumors. A preparation for encapsulating malignant tumor tissues is also provided which comprises batroxobin and therefore can cause or promote formation of capsule-like tissue around malignant tumor tissues.
    Type: Application
    Filed: December 13, 2006
    Publication date: May 10, 2007
    Applicant: TOBISHI PHARMACEUTICAL CO., LTD.
    Inventors: Hirobumi Senga, Yongling Wan, Lishui Chang
  • Publication number: 20060088519
    Abstract: A malignant tumor-inhibiting preparation is provided which comprises Des A fibrin and therefore can inhibit the spreading and migration of malignant tumor cells and thereby can inhibit the malignant tumors.
    Type: Application
    Filed: December 21, 2005
    Publication date: April 27, 2006
    Applicant: Tobishi Pharmaceutical Co., Ltd.
    Inventors: Hirobumi Senga, Caixia Li, Yongling Wan, Lishui Chang